The stock has declined 11% in the trailing 52 weeks. Since the start of this year though, the stock has somewhat recovered, gaining 14%.
Brian Humphries, who took charge as Cognizant CEO on April 1, said, “While I am encouraged by our client centricity, our employees’ winning spirit, and our innovation, we are not yet delivering against the market opportunity.”
The company expects the ongoing execution of its long-term strategy to drive revenue and earnings growth in the current fiscal year. However, a weak first quarter forced the company to slash its full-year guidance.
READ: IMMUNOGEN IS CHEAP AHEAD OF EARNINGS, BUT IS IT WORTH?
The outlook for full-year revenue growth was slashed to 3.6% to 5.1%, from the prior guidance range of 7% to 9%. Full year adjusted EPS is now expected in the range of $3.87-$3.95, compared to the earlier projection of $4.40.
Meanwhile, the growth forecast for the second quarter was projected between 3.9% and 4.9%.
CFO Karen McLoughlin said, “Our revised full-year outlook reflects the first-quarter underperformance and expectations of slower growth in Financial Services and Healthcare for the remainder of 2019.”